Xyall has been identified as a next-generation global innovator in molecular pathology, winning investment of €5 million from partners such as Sioux Technologies, BOM Brabant Ventures, the Netherlands Enterprise Agency, and other private investors.
Tissue dissection remains a labour-intensive process, based on subjective analysis, at risk of error and cross-contamination. Xyall aims to transform the way laboratories carry this out, by delivering higher precision, speed and sensitivity in whole-slide imaging, registration and workflow optimisation in combination with high-precision, robotic solutions.
Several US and European hospital laboratories have already contracted with Xyall to trial a prototype of the new automated system. Guido du Pree, Xyall’s CEO, explained: “Molecular diagnostic tests provide key clinical information to physicians to enable them to target the most appropriate treatment based on a patient’s individual biology. This is especially vital when testing for cancer. Clinicians and laboratory scientists are calling for faster and more accurate tissue dissection solutions to help them deliver precision medicine. They also want an automated system which makes the most efficient use of existing staffing levels.”
https://xyall.com/our-solution/
